BioCentury

7:00 AM GMT, Apr 30, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Okairos: The evasive adenovirus

It's well known that adenovirus is a useful delivery system for eliciting T cell responses against pathogenic antigens. However, the virus is so common that many people have antibodies that inactivate it. This lack of potency has limited the use of adenovirus as a vector for many vaccines.

Okairos AG says its researchers modified the virus to evade neutralizing antibodies while they were part of

Read the full 656 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.